Nelson Advisors Guide for Founders to HealthTech and MedTech Success in 2026: 10 European Case Studies

Europe has quietly become one of the most productive regions on earth for building health and medical technology companies of genuine scale. Over the past decade a cohort of founders has turned the continent's structural disadvantages, fragmented markets, multiple regulators, conservative public payers, slow procurement, into the very foundations of durable, defendable businesses. This guide examines ten of them in depth.

The companies profiled here are deliberately varied. They span pure software platforms (Doctolib, Ada Health, Kry/Livi), deep-science instrumentation (Oxford Nanopore), surgical robotics (CMR Surgical), applied genomics and AI biology (SOPHiA GENETICS, Owkin), clinical-AI infrastructure (Corti), tech-enabled care delivery (Cera) and preventive consumer medicine (Neko Health). Between them they have raised well over five billion euros from grants, venture capital, private equity, strategic pharmaceutical partners and the public markets. Some are now profitable; several are not; one cautionary comparator in this report went bankrupt after a multi-billion-dollar valuation.
 
Three themes run through every case. 

First, the most defendable moats in European health technology are built not from clever algorithms but from proprietary data, regulatory clearance and entrenchment in the workflows of clinicians and payers, assets that take years to accumulate and are extremely hard to copy. 
  
Second, the distinction between being “AI-native” and an “AI enabler” matters far less than founders assume: what matters is whether AI is layered on top of a genuine distribution and data advantage. 
  
Third, the 2022–24 funding winter separated the survivors from the casualties almost entirely on the basis of capital discipline and proximity to whoever actually pays for healthcare.
  
This is not a ranking. It is a working reference for founders and boards: a set of strategies, tactics, funding journeys, critical decisions and hard-won lessons drawn from companies that have already walked the path you are on. Read it as a map of what has worked, what has nearly killed otherwise excellent businesses, and where the genuinely defensible value in this market sits in 2026.
 
How to read this guide

▸ Each case study opens with a fact box (HQ, founders, funding, valuation, AI posture) followed by analysis of strategy, scalability, moat, risks, critical decisions and lessons.

▸ Funding figures are drawn from company announcements and reputable reporting to mid-2026; private valuations are last-round marks and may be stale. Treat them as directional, not audited.

▸ Cross-cutting chapters after the case studies synthesise the patterns: AI-native versus AI-enabler, moat construction, the funding map, and the risks that have sunk well-capitalised peers.
  
The 2026 landscape: why these lessons matter now
  
Founders entering HealthTech and MedTech in 2026 face a market that looks superficially similar to 2021 but behaves completely differently. The exuberant capital of the pandemic era has gone; in its place is a more demanding investor base that wants evidence of clinical impact, a credible path to profitability and a defensible position before it writes large cheques. At the same time, the underlying demand has never been stronger. Ageing populations, chronic disease burden, workforce shortages across European health systems and the maturation of artificial intelligence have combined to make health one of the few categories where technology can simultaneously cut cost and improve outcomes.
  
The opportunity is therefore real, but the bar is higher. The companies in this report succeeded not because they rode a hype cycle but because they solved a structural problem for a payer, a clinician or a patient and then made that solution progressively harder to displace. Understanding how they did it and where comparable companies failed, is the single most useful preparation a founder can do.
  
A simple framework: scalable, sustainable, defendable
  
Throughout this guide we assess each company against three properties that, in our advisory work, separate enduring health-technology businesses from those that raise large rounds and then stall.
  
•     Scalable — can the business add revenue faster than it adds cost? Software platforms scale through near-zero marginal cost; hardware and care businesses scale through repeatable unit models, manufacturing capacity or acquisition roll-ups. The question is always: what is the unit, and does the next unit get cheaper?
  
•     Sustainable — does the business have a route to funding itself? In a market where reimbursement is slow and capital is expensive, the survivors are those with recurring revenue, demonstrated unit economics and the discipline to reach profitability before the money runs out.
  
•     Defendable — once the business works, how hard is it to copy? In health the durable moats are proprietary longitudinal data, regulatory clearance, entrenchment in clinical workflows, patent estates and trusted brand. Features are not moats; the assets that take years to build are.
 
With that framework in mind, we turn to the ten companies.
  
Why these ten companies
  
These ten were not chosen as a definitive ranking of the best European health-technology companies, nor as an investment recommendation. They were selected because, between them, they illustrate the full range of strategies, business models, funding paths and moats a founder is likely to consider, also because each has progressed far enough to offer real, tested lessons rather than early promise.
  
The selection deliberately spans the spectrum from pure software to deep science. Doctolib, Ada Health and Kry/Livi represent software-led platforms and digital care. Oxford Nanopore and CMR Surgical represent capital-intensive deep-science hardware. SOPHiA GENETICS and Owkin sit at the data-and-AI layer of genomics and drug discovery. Corti represents pure clinical-AI infrastructure. Cera represents technology-enabled care delivery, and Neko Health represents consumer-facing preventive medicine. The set also spans the funding journey, from companies still private and venture-backed, through those that took strategic capital from industry partners, to two that have weathered the public markets — and several European geographies, with companies anchored in France, the United Kingdom, Switzerland, Germany, Sweden and Denmark.
  
Just as importantly, the cohort spans outcomes. Some are profitable; several are not; valuations have risen for some and fallen sharply for others. We have resisted the temptation to present only unambiguous successes, because the most useful lessons frequently lie in the tensions, a brilliant business with a punished share price, a category creator still searching for profitability, an AI pioneer confronting a new paradigm. Read together, they form a more honest map of the territory than a list of winners would.

Click here to read the report in full https://www.healthcare.digital/single-post/the-nelson-advisors-guide-for-founders-to-healthtech-and-medtech-success-in-2026-10-european-case-s